Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Acquired by Daiwa Securities Group Inc.

Daiwa Securities Group Inc. lifted its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 10.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 89,465 shares of the company’s stock after purchasing an additional 8,100 shares during the period. Daiwa Securities Group Inc.’s holdings in Teva Pharmaceutical Industries were worth $1,612,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in the company. Clal Insurance Enterprises Holdings Ltd lifted its stake in shares of Teva Pharmaceutical Industries by 6.8% in the 3rd quarter. Clal Insurance Enterprises Holdings Ltd now owns 34,543,812 shares of the company’s stock valued at $621,337,000 after purchasing an additional 2,204,623 shares during the period. Renaissance Technologies LLC lifted its stake in shares of Teva Pharmaceutical Industries by 13.4% in the 2nd quarter. Renaissance Technologies LLC now owns 8,728,563 shares of the company’s stock valued at $141,839,000 after purchasing an additional 1,031,400 shares during the period. Truist Financial Corp lifted its stake in shares of Teva Pharmaceutical Industries by 7.0% in the 2nd quarter. Truist Financial Corp now owns 3,885,251 shares of the company’s stock valued at $63,135,000 after purchasing an additional 254,483 shares during the period. Swiss National Bank lifted its stake in shares of Teva Pharmaceutical Industries by 0.5% in the 3rd quarter. Swiss National Bank now owns 3,342,900 shares of the company’s stock valued at $60,239,000 after purchasing an additional 15,300 shares during the period. Finally, National Pension Service lifted its stake in shares of Teva Pharmaceutical Industries by 107.3% in the 3rd quarter. National Pension Service now owns 3,170,640 shares of the company’s stock valued at $57,135,000 after purchasing an additional 1,640,940 shares during the period. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Price Performance

Teva Pharmaceutical Industries stock opened at $16.57 on Friday. Teva Pharmaceutical Industries Limited has a 52-week low of $9.35 and a 52-week high of $19.31. The firm has a market capitalization of $18.77 billion, a price-to-earnings ratio of -19.49, a PEG ratio of 1.30 and a beta of 0.87. The company has a fifty day simple moving average of $17.57 and a 200-day simple moving average of $17.35. The company has a quick ratio of 0.61, a current ratio of 0.89 and a debt-to-equity ratio of 2.57.

Insider Transactions at Teva Pharmaceutical Industries

In other news, EVP Christine Fox sold 19,388 shares of the company’s stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total transaction of $327,075.56. Following the completion of the sale, the executive vice president now owns 44,104 shares of the company’s stock, valued at $744,034.48. This represents a 30.54 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.55% of the company’s stock.

Analyst Ratings Changes

TEVA has been the subject of several analyst reports. Barclays boosted their target price on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the company an “overweight” rating in a research note on Wednesday, October 23rd. StockNews.com raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Thursday, October 17th. JPMorgan Chase & Co. boosted their price target on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a report on Monday, October 21st. Finally, UBS Group boosted their price target on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday, September 3rd. Two analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $19.67.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.